The DOI matches its Crossref record.
Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Abstract
Nitric oxide (NO), a molecular messenger synthesized by nitric oxide synthase (NOS) from L-arginine and molecular oxygen, is involved in a number of physiological and pathological processes in mammalians. Three structurally distinct isoforms of NOS have been identified: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). Although NO mediates several physiological functions, overproduction of NO by nNOS has been reported in a number of clinical disorders including acute (stroke) and chronic (schizophrenia, Alzheimer s, Parkinson s and AIDS dementia) neurodegenerative diseases, convulsions and pain; overproduction of NO by iNOS has been implicated in various pathological processes including septic shock, tissue damage following inflammation and rheumatoid arthritis. On the contrary, NO produced by eNOS has only physiological roles such as maintaining physiological vascular tone. Accordingly, selective inhibition of nNOS or iNOS vs eNOS may provide a novel therapeutic approach to various diseases; in addition selective inhibitors may represent useful tools for investigating other biological functions of NO. For these reasons, after the identification of N-methyl-L-arginine (L-NMA) as the first inhibitor of NO biosynthesis, design of selective NOS inhibitors has received much attention. In this article the recent developments of new molecules endowed with inhibitory properties against the various isoforms of NOS are reviewed. Major focus is placed on structure-activity-selectivity relationships especially concerning compounds belonging to the non-amino acid-based inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543
The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels
Toda, N., & Okamura, T. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.3 · Cited by 308
Lee, A. K., Sung, S. H., Kim, Y. C., & Kim, S. G. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705231 · Cited by 279
Nitric oxide and S-nitrosothiols in human blood
Giustarini, D., Milzani, A., Colombo, R., Dalle-Donne, I., & Rossi, R. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00046-9 · Cited by 136
KIANG, J. G. (2004) · Cell Research · doi:10.1038/sj.cr.7290247 · Cited by 63
Metadata
- Authors
- Saleron, L., Sorrenti, V., Giacomo, C., Romeo, G., & Siracusa, M.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-02-01
- Volume
- 8
- Issue
- 3
- Pages
- 177-200
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2137244891
- Cited by
- 214
- References
- 0
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors. https://app.cochat.ai/papers/10.2174/1381612023396375
- The paper
- Saleron, L., Sorrenti, V., Giacomo, C., Romeo, G., & Siracusa, M. (2002). Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors. Current Pharmaceutical Design. https://doi.org/10.2174/1381612023396375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.